Chilamakuri CS, Lorenz S, Madoui MA, *et al.* (2014) Performance comparison of four exome capture systems for deep sequencing. BMC Genomics 15:449.

Chin E, Zhang V, Wang J, *et al.* (2013) Frequently asked questions about the clinical utility of next-generation sequencing in molecular diagnosis of human genetic diseases. In: Wong L-JC (ed) Next Generation Sequencing: Translation to Clinical Diagnostics. Springer Science + Business Media, New York, pp 287–299.

Chun S, Fay JC (2009) Identification of deleterious mutations within three human genomes. Genome Res 19:1553–1561.

Cingolani P, Platts A, Wang le L, *et al.* (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w^{1118}; iso-2; iso-3. Fly 6:80–92.

Cooper DN, Ball EV, Krawczak M (1998) The human gene mutation database. Nucleic Acids Res 26:285–287.

De Luca A, Bottillo I, Dasdia MC, *et al.* (2007) Deletions of *NF1* gene and exons detected by multiplex ligation-dependent probe amplification. J Med Genet 44:800–808.

Fahsold R, Hoffmeyer S, Mischung C, *et al.* (2000) Minor lesion mutational spectrum of the entire *NF1* gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Hum Genet 66:790–818.

Frommolt P, Abdallah AT, Altmüller J, *et al.* (2012) Assessing the enrichment performance in targeted resequencing experiments. Hum Mutat 33:635–641.

Gasparini P, D'Agruma L, Pio de Cillis G, *et al.* (1996) Scanning the first part of the neurofibromatosis type 1 gene by RNA-SSCP: identification of three novel mutations and of two new polymorphisms. Hum Genet 97:492–495.

Han SS, Cooper DN, Upadhyaya MN (2001) Evaluation of denaturing high performance liquid chromatography (DHPLC) for the mutational analysis of the neurofibromatosis type 1 (NF1) gene. Hum Genet 109:487–497.

Hattori M, Torii C, Yagihashi T, *et al.* (2009) Diagnosis of Russell-Silver syndrome by the combined bisulfite restriction analysis—denaturing high-performance liquid chromatography assay. Genet Test Mol Biomarkers 13:623–630.

Japanese Genetic Variation Consortium (2013) Human genetic variation browser. Available at www.genome.med.kyoto-u.ac.jp/SnpDB (accessed March 18 2014).

Jones K (2005) Smith's Recognizable Patterns of Human Malformation. Saunders, Philadelphia.

Kosaki K, Udaka T, Okuyama T (2005) DHPLC in clinical molecular diagnostic services. Mol Genet Metab 86:117–123.

Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081.

Lee MJ, Su YN, You HL, *et al.* (2006) Identification of forty-five novel and twenty-three known *NF1* mutations in Chinese patients with neurofibromatosis type 1. Hum Mutat 27:832.

Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler Transform. Bioinformatics 25:1754–1760.

Li Y, Bollag G, Clark R, *et al.* (1992) Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 69:275–281.

McKenna A, Hanna M, Banks E, *et al.* (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297–1303.

Messiaen LM, Callens T, Mortier G, *et al.* (2000) Exhaustive mutation analysis of the *NF1* gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 15:541–555.

Nemethova M, Bolcekova A, Ilencikova D, *et al.* (2013) Thirty-nine novel neurofibromatosis 1 (NF1) gene mutations identified in Slovak patients. Ann Hum Genet 77:364–379.

Neurofibromatosis Conference Statement (1988) National Institutes of Health Consensus Development Conference. Arch Neurol 45:575–578.

Purandare SM, Huntsman Breidenbach H, *et al.* (1995) Identification of neurofibromatosis 1 (NF1) homologous loci by direct sequencing, fluorescence *in situ* hybridization, and PCR amplification of somatic cell hybrids. Genomics 30:476–485.

Purandare SM, Lanyon WG, Connor JM (1994) Characterisation of inherited and sporadic mutations in neurofibromatosis type-1. Hum Mol Genet 3:1109–1115.

Richards CS, Bale S, Bellissimo DB, *et al.* (2008) ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med 10:294–300.

Rozen S, Skaletsky H (2000) Primer3 on the www for general users and for biologist programmers. Methods Mol Biol 132:365–386.

Sabbagh A, Pasmant E, Imbard A, *et al.* (2013) NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience. Hum Mutat 34:1510–1518.

Samejima H, Torii C, Kosaki R, *et al.* (2007) Screening for Alagille syndrome mutations in the *JAG1* and *NOTCH2* genes using denaturing high-performance liquid chromatography. Genet Test Mol Biomarkers 11:216–227.

Schwarz JM, Rödelsperger C, Schuelke M, *et al.* (2010) MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 7:575–576.

Siepel A, Pollard KS, Haussler D (2009) New methods for detecting lineage-specific selection. Proceedings of the 10th International Conference on Research in Computational. Mol Biol 3909:190–205.

Takenouchi T, Hida M, Sakamoto Y, *et al.* (2013a) Severe congenital lipodystrophy and a progeroid appearance: mutation in the penultimate exon of *FBN1* causing a recognizable phenotype. Am J Med Genet A 161A:3057–3062.

Takenouchi T, Matsuzaki Y, Torii C, *et al.* (2014) *SOX9* dimerization domain mutation mimicking type 2 collagen disorder phenotype. Eur J Med Genet 57:298–301.

Takenouchi T, Shimizu A, Torii C, *et al.* (2013b) Multiple Café au Lait spots in familial patients with *MAP2K2* mutation. Am J Med Genet A 164A:392–396.

Teer JK, Green ED, Mullikin JC, *et al.* (2012) VarSifter: visualizing and analyzing exome-scale sequence variation data on a desktop computer. Bioinformatics 28:599–600.

Thorvaldsdóttir H, Robinson JT, Mesirov JP (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14:178–192.

Udaka T, Imoto I, Aizu Y, *et al.* (2007) Multiplex PCR/liquid chromatography assay for screening of subtelomeric rearrangements. Genet Test Mol Biomarkers 11:241–248.

Udaka T, Kurosawa K, Izumi K, *et al.* (2006) Screening for partial deletions in the *CREBBP* gene in Rubinstein-Taybi syndrome patients using multiplex PCR/liquid chromatography. Genet Test Mol Biomarkers 10:265–271.

Udaka T, Torii C, Takahashi D, *et al.* (2005) Comprehensive screening of the thiopurine methyltransferase polymorphisms by denaturing high-performance liquid chromatography. Genet Test Mol Biomarkers 9:85–92.

Upaddhyaya M (2008) *NF1* gene structure and *NF1* genotype/phenotype correlations. In: Kaufmann D (ed) Neurofibromatoses. Karger, Basel, pp 46–62.

Valero MC, Martín Y, Hernández-Imaz E, *et al.* (2011) A highly sensitive genetic protocol to detect NF1 mutations. J Mol Diagn 13:113–122.

Yan D, Tekin M, Blanton SH, *et al.* (2013) Next-generation sequencing in genetic hearing loss. Genet Test Mol Biomarkers 17:581–587.

Address correspondence to:
Kenjiro Kosaki, MD, FACMG
Center for Medical Genetics
Keio University School of Medicine
35 Shinanomachi, Shinjuku-ku
Tokyo 160-8582
Japan

E-mail: kkosaki@z3.keio.jp